Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
382.00
-10.00 (-2.55%)
Nov 24, 2025, 4:00 PM EST
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,189
Profits / Employee
$114,831
Market Cap
329.10B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
Roche Holding AG News
- 5 days ago - Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution - Seeking Alpha
- 5 days ago - KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors - Business Wire
- 6 days ago - Roche: European Commission Grants Conditional Marketing Authorisation Of Lunsumio - Nasdaq
- 6 days ago - European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma - GlobeNewsWire
- 6 days ago - Market bubbles cracking: Gold & defense stocks the go‑to strategy, says David Roche - CNBC
- 6 days ago - Why biotech and drug stocks are on the mend even though the rest of the market is hurting - Market Watch
- 6 days ago - RHHBY Reports Positive Phase III Data on Breast Cancer Drug - Nasdaq
- 6 days ago - Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock - Benzinga